Palvella Therapeutics Inc/$PVLA
1D1W1MYTD1Y5YMAX
Capital at risk
About Palvella Therapeutics Inc
Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company whose vision is to become the rare disease biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no FDA-approved therapies. Its product candidate, QTORIN 3.9% rapamycin anhydrous gel, is currently in clinical development for microcystic lymphatic malformations and cutaneous venous malformations. It operates in single segment.
- Ticker
- $PVLA
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- -
- Headquarters
- Wayne, United States
- Website
- palvellatx.com
PVLA Metrics
BasicAdvanced
$2.2B
-
-$4.90
-
-
Price and volume
Market cap
$2.2B
52-week high
$161.38
52-week low
$54.48
Average daily volume
187K
Financial strength
Current ratio
21.179
Quick ratio
21.008
Long term debt to equity
0.103
Total debt to equity
0.104
Interest coverage (TTM)
-7.60%
Profitability
Management effectiveness
Return on assets (TTM)
-22.05%
Return on equity (TTM)
-46.63%
Valuation
Price to book
10.05
Price to tangible book (TTM)
10.05
Price to free cash flow (TTM)
-52.242
Free cash flow yield (TTM)
-1.91%
Free cash flow per share (TTM)
-2.899
Growth
Earnings per share change (TTM)
19.98%
Bulls say / Bears say
The February 24, 2026 Phase 3 SELVA study for QTORIN™ rapamycin met its primary endpoint with statistically significant improvements across all pre-specified secondary endpoints and reported no drug-related serious adverse events, underscoring a strong efficacy and safety profile. (Reuters)
On June 22, 2026, the FDA granted rolling review for Palvella’s QTORIN™ rapamycin NDA for microcystic lymphatic malformations, allowing the Agency to begin evaluating completed sections of the application as they become available, which could accelerate regulatory approval. (Reuters)
Palvella’s common stock was approved for transfer to the Nasdaq Global Market effective May 13, 2026, reflecting compliance with higher listing standards and likely broadening the company’s visibility and appeal to institutional investors. (Reuters)
Palvella posted a Q2 net loss of $21.9 million, or $1.52 per share, up from $9.5 million a year earlier as R&D expenses more than doubled to $12.5 million, accelerating cash burn and increasing dilution risk. (Reuters)
The Phase 2 TOIVA trial’s bleeding cohort included only four patients, limiting statistical robustness and raising uncertainty over whether these results will translate to larger pivotal studies. (Reuters via Investing.com)
QTORIN™ pitavastatin for DSAP remains in early development with Phase 2 initiation not expected until H2 2026, offering no clinical efficacy data to de-risk the program and potentially diverting resources. (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 7 Sept 2026.
Upcoming events
No upcoming events
PVLA News
AllArticlesVideos
Funds containing PVLA
AllEURUSDGBP
Fund name | Fund size | $PVLA weighting |
|---|---|---|
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.06% |
iShares MSCI World Small Cap$WSML | $9B | 0.02% |
iShares MSCI World Small Cap€IUSN | €7.8B | 0.02% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | €2.8B | 0.02% |
iShares MSCI USA Small Cap CTB Enhanced ESG£CUS1 | £2.4B | 0.02% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.